Name | Gemcitabine Hydrochloride |
Synonyms | gemzar ly188011 Gemcitabine HCl ly188011hydrochloride Gemcitabine hydrochlorid Gemcitabine Hydrochloride 2',2'-DIFLUORO-2'-DEOXYCYTIDINE 2',2'-Difluoro-2'-deoxycytidine 2'-DEOXY-2',2'-DIFLUOROCYTIDINE 2,2-Difluoro-2-deoxycytidine DDFC 2',2'-difluorodeoxycytidinemonohydrochloride 2',2'-Difluoro-2'-deoxycytidine hydrochloride 2'-deoxy-2',2'-difluorocytidinemonohydrochloride 2'-deoxy-2',2'-difluoro-cytidinmonohydrochloride 4-amino-1-(2-deoxy-2,2-difluoropentofuranosyl)pyrimidin-2(1H)-one 4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-pyrimidin-2-one hydrochloride |
CAS | 122111-03-9 |
EINECS | 601-823-3 |
InChI | InChI=1/C9H11F2N3O4.ClH/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17;/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17);1H |
Molecular Formula | C9H12ClF2N3O4 |
Molar Mass | 299.66 |
Melting Point | >250°C dec. |
Boling Point | 482.7°C at 760 mmHg |
Specific Rotation(α) | D +48°; 365 +257.9° (c = 1.0 in deuterated water) |
Flash Point | 245.7°C |
Solubility | H2O: ≥10mg/mL |
Vapor Presure | 2.41E-11mmHg at 25°C |
Appearance | Crystalline powder |
Color | White |
Maximum wavelength(λmax) | ['268nm(H2O)(lit.)'] |
Merck | 14,4386 |
Storage Condition | 2-8°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20° for up to 1 month. |
MDL | MFCD01735988 |
Use | Suitable for the treatment of inoperable advanced or metastatic pancreatic cancer and the treatment of locally advanced or metastatic non-small cell lung cancer, the treatment of advanced non-small cell lung cancer, non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer and other solid tumors. |
In vitro study | Gemcitabine acts on BxPC-3, PANC-1, and MIA PaCa-2 cells, induces NF-κB activity, acts on BxPC-3 and PANC-1 cells, and decreases NF-κB inhibitor IκBα levels. Low-dose Gemcitabine treatment of BxPC-3 cells for 48 hours increased NF-κB binding in a dose-dependent manner. In contrast, treatment of BxPC-3 cells with higher doses of Gemcitabine for 48 hours decreased NF-κB DNA binding, while treatment of BxPC-3 cells with higher doses of Gemcitabine for 24 hours increased NF-κB binding. |
In vivo study | The intratumoral NF-κB activity was significantly increased (1.3-to 1.8-fold) in Gemcitabine-treated mice compared to PBS-treated mice, indicating that Gemcitabine also induces NF-κB activity. |
Risk Codes | R21 - Harmful in contact with skin R36/38 - Irritating to eyes and skin. R46 - May cause heritable genetic damage R62 - Possible risk of impaired fertility R63 - Possible risk of harm to the unborn child |
Safety Description | S25 - Avoid contact with eyes. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36/37 - Wear suitable protective clothing and gloves. S53 - Avoid exposure - obtain special instructions before use. |
WGK Germany | 3 |
RTECS | HA3840000 |
HS Code | 29420000 |
Reference Show more | 1. Duan Tong, Li Jinsong. Effect of micro-RNA-615-3p down-regulation of pigment frame homologous protein 6 on lung cancer gemcitabine chemotherapy resistant cell lines and its mechanism [J]. Chinese Journal of Clinical Pharmacology, 2021,37(04):416-420. |
This product is 2 '-Deoxy-2',2 '-difluorocytidine isomer) hydrochloride. The content of C9H11F2N3O4 • HCl should be between 98.0% and 102.0% based on the dry product.
take this product, precision weighing, adding water to dissolve and dilute the solution containing about 10 mg per 1 ml, according to the law (General 0621), the specific rotation is 43 ° to 50 °.
take 0.10g of this product, Add 10ml of water to dissolve it, and determine it according to law (General rule 0631). The pH value should be 2.0~3.0.
take 0.10g of this product and add 0902 of water to dissolve the solution. The solution should be clear and colorless. If it is turbid, it should not be deeper compared with No. 1 turbidity standard solution (General rule first method).
precision weigh the appropriate amount of this product, add water to dissolve and quantitatively dilute the solution containing about 2mg per 1 ml, as a test solution; an appropriate amount of gemcitabine hydrochloride control substance and cytosine (impurity I) was accurately weighed, dissolved with water and quantitatively diluted to prepare a solution containing about 2ug per 1 ml, which was used as a control solution. According to the determination of high performance liquid chromatography (General 0512), using octyl silane bonded silica gel as filler, 0.14mol/L phosphate buffer (take sodium dihydrogen phosphate 13.8g and phosphoric acid 2.5, add water to dissolve and dilute to 1000ml,pH value should be 2.5±0.1)-methanol (97:3) as mobile phase A, 0.14mol/L phosphate buffer-methanol (50:50) as mobile phase B; gradient elution was carried out according to the following table (if necessary, adjust the chromatographic system so that gemcitabine peaks within 8 minutes), and the detection wavelength was 275nm. The system applicable solution 20 u1 under the content determination item was injected into the liquid chromatograph, and the chromatogram was recorded. The order of peaks was cytosine peak, a-isomer (impurity II) peak and gemcitabine peak, the resolution between the-isomer peak and the gemcitabine peak should be greater than 8.0 and the tailing factor of the gemcitabine peak should not be greater than 1.5. 20 u1 of the test solution and the reference solution were respectively injected into the liquid chromatograph, and the chromatograms were recorded. If there are impurity peaks in the chromatogram of the test solution, cytosine shall not exceed 0.1% based on peak area calculated by external standard method, and the remaining impurities shall not exceed 0.1% based on gemcitabine peak area calculated by external standard method, other individual unknown impurities shall not exceed 0.1%, and the total amount of impurities shall not exceed 0.2%. Impurity peaks with a content of less than 0.02% are negligible.
take this product, dry to constant weight at 105°C, weight loss shall not exceed 1.0% (General rule 0831).
take l.Og of this product and check it according to law (General rule 0841 eight residues shall not exceed 0.1%.
The residue left under the item of ignition residue shall not be more than 10 parts per million (ppm) and shall be inspected according to law (General rule 0821 second law).
measured by high performance liquid chromatography (General 0512).
A mobile phase of 0.14mol/L phosphate buffer (pH 2.5 )-methanol (97:3) was used with octanosilane-bonded silica gel as a filler, and the detection wavelength was 275nm. Take about 10 mg of gemcitabine hydrochloride control, put it in a 100ml measuring flask, add potassium hydroxide methanol solution (take potassium hydroxide 1.68g, add methanol 10ml, shake to dissolve) 4ml, Seal, ultrasonic to dissolve, heat at 55°C water bath for 6-16 hours, let cool, dilute to scale with 1% Phosphoric acid solution, shake well, as a system-suitable solution (about 0.02mg isomer per 1 ml). 20ul of the applicable solution of the system is taken, and human liquid chromatography is injected to record the chromatogram. The resolution between the isomer peak and gemcitabine peak should be greater than 8.0, and the tailing factor of gemcitabine peak should not be greater than 1.5.
take an appropriate amount of this product, weigh it accurately, add water to dissolve and quantitatively dilute it to make it contain about 0 in each lml. 1 mg solution was used as the test solution, and 20 u1 was accurately measured, and the human liquid chromatograph was injected, and the chromatogram was recorded. In addition, an appropriate amount of gemcitabine hydrochloride reference substance was taken, and the same method was used for determination. According to the external standard method to calculate the peak area, that is.
antineoplastic agents.
shade, Seal, store in a cool and dry place.
This product is a sterile freeze-dried product of gemcitabine hydrochloride, containing gemcitabine hydrochloride according to gemcitabine (C9H11F2N304), which should be 95.0% ~ 105.0% of the label amount.
This product is white loose lumps or powder.
Take 3 bottles of this product, add water to dissolve and quantitatively dilute the solution containing 0.1mg of gemcitabine in each lml, as the test solution, the assay was performed according to the method under the gemcitabine hydrochloride assay. According to the external standard method, the peak area is calculated, and the result is multiplied by 0.8783, and the average value of 3 bottles is calculated.
with gemcitabine hydrochloride.
(1)0.2g (2) 1.0g
sealed and stored in a dry place.